Skip to content

ANI Pharmaceuticals Inc

ANIP· NasdaqCore metricsCIK 1023024

Pharmaceutical preparations553 peers

Last sale
Nov 12, 2026 · -0.49%
Market cap
$1.60B
22.49M shares
Filings
1,047
$290.78M
Q3 2026+43.8% FY25 yoy
$35.15M
Q3 2026N/M FY25 yoy
$52.37M
Q3 2026+18,922.8% FY25 yoy
$176.20M
Q3 2026derived+258.7% FY25 yoy
$1.51
Q3 2026N/M FY25 yoy
$420.76M
Q3 2026+97.1% FY25 yoy
$1.60B
13.7×
1.5×
2.5×
12.86%
0.00%

Twelve months to Sep 30, 2026 · derived

Price

$70.9819.83%$17.56past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$883.37MFY 2025
$883.37M0FY 2014FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$883,366,000reported
FY 20242024-12-31$614,376,000reported
FY 20232023-12-31$486,816,000reported
FY 20222022-12-31$316,385,000reported
FY 20212021-12-31$216,136,000reported
FY 20202020-12-31$208,475,000reported
FY 20192019-12-31$206,547,000reported
FY 20182018-12-31$201,576,000reported
FY 20172017-12-31$176,842,000reported
FY 20162016-12-31$128,622,000reported
FY 20152015-12-31$76,322,000reported
FY 20142014-12-31$55,970,000reported

Capital returns

Dividends and buybacks · FY2016 to FY2025
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2025$1.16M$12.21M$13.37M—22.49M sh+6.6%7.8%
FY2024$1.63M$10.96M$12.58M—21.11M sh—26.3%
FY2023$1.63M$4.99M$6.61M———6.0%
FY2022$1.63M$1.96M$3.58M————
FY2021$190.00K$890.00K$1.08M———141.2%

Segments

Revenue by Segments, FY2020 to FY2025FY2020Generics, Established Brands and Other · FY2020 · $208.48MFY2021Generics, Established Brands and Other · FY2021 · $216.14MFY2022Rare Disease and Brands · FY2022 · $81.15MGenerics and Other · FY2022 · $235.24MGenerics, Established Brands and Other · FY2022 · $274.70MRare Disease · FY2022 · $41.69MFY2023Rare Disease and Brands · FY2023 · $197.50MGenerics and Other · FY2023 · $289.31MGenerics, Established Brands and Other · FY2023 · $374.70MRare Disease · FY2023 · $112.12MFY2024Rare Disease and Brands · FY2024 · $294.34MGenerics and Other · FY2024 · $320.03MFY2025Rare Disease and Brands · FY2025 · $483.93MGenerics and Other · FY2025 · $399.43M
LineFY2025ShareChange
Rare Disease and Brands$483.93M55%+64.4%
Generics and Other$399.43M45%+24.8%
Generics, Established Brands and Other———
Rare Disease———
Total$883.37M

From the 10-K filed Feb 27, 2026ANIP

Pharmaceutical preparations

ANI Pharmaceuticals Inc is the 38th largest of the 554 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

ANI Pharmaceuticals Inc · CIK 1023024 · Engraved from SEC EDGAR